Healthcare Expenditure for Treatment of Cardiovascular Disease Among Hypercholesterolemia Patients in Japan: A Claims Data Analysis
Author(s)
Tomohiro Kondo, MSc1, Yilong Zhang, MD2, Kentaro Yamato, PhD3.
1HEOR/RWE, Otsuka Phamaceutical Co.,Ltd., Minato-ku, Japan, 2Otsuka phamaceutical Co., Ltd., Tokyo, Japan, 3Otsuka Holdings Co., Ltd., Tokyo, Japan.
1HEOR/RWE, Otsuka Phamaceutical Co.,Ltd., Minato-ku, Japan, 2Otsuka phamaceutical Co., Ltd., Tokyo, Japan, 3Otsuka Holdings Co., Ltd., Tokyo, Japan.
OBJECTIVES: Hypercholesterolemia is a major modifiable risk factor for cardiovascular disease (CVD) in Japan. CVD, particularly stroke and coronary heart disease, are leading causes of death in Japan, with their burden expected to rise due to an aging population and increasing cardiovascular risk factors. A proper understanding of the financial impact of CVD is important for appropriate allocation of healthcare resources. In this study, we analyzed the medical care expenditures of CVD in Japan using claims data.
METHODS: In this study, we used data from medical institutions using the Diagnosis Procedure Combination system obtained from Medical Data Vision (Tokyo, Japan) from April 2008 to March 2024.This analysis was conducted using Prospection’s analytics platform to identify cardiovascular events and estimate the direct medical costs of ischemic stroke (IS), myocardial infarction (MI), and unstable angina (UA), which were defined using ICD-10 codes as follows: MI (I21-I22), IS (I63), and UA (I20.0).
RESULTS: A total of CVD patients were identified, with a mean age of 72.3 years and a male ratio of 68.8%. A total of 52,268 MI events were identified, including 50,313 with a primary event. Among primary MI patients, the first-year treatment cost was ¥2,769,173, and ¥771,857 annually thereafter. For secondary MI patients, the first-year cost was ¥2,781,067, and ¥1,024,076 annually thereafter. Among 28,460 UA patients, 22,358 had a primary event. The first-year cost for primary UA patients was ¥2,190,184, and ¥743,372 annually thereafter; for secondary UA patients, the first-year cost was ¥1,916,954, and ¥858,116 annually. Among 79,476 IS patients, 70,563 experienced a primary event. The first-year treatment cost was ¥2,124,713 for primary IS patients and ¥768,141 annually thereafter; for secondary IS patients, the first-year cost was ¥2,105,041 and ¥865,710 annually thereafter.
CONCLUSIONS: Based on this large and contemporary real-world study, CVD present a substantial cost burden to the Japanese healthcare system.
METHODS: In this study, we used data from medical institutions using the Diagnosis Procedure Combination system obtained from Medical Data Vision (Tokyo, Japan) from April 2008 to March 2024.This analysis was conducted using Prospection’s analytics platform to identify cardiovascular events and estimate the direct medical costs of ischemic stroke (IS), myocardial infarction (MI), and unstable angina (UA), which were defined using ICD-10 codes as follows: MI (I21-I22), IS (I63), and UA (I20.0).
RESULTS: A total of CVD patients were identified, with a mean age of 72.3 years and a male ratio of 68.8%. A total of 52,268 MI events were identified, including 50,313 with a primary event. Among primary MI patients, the first-year treatment cost was ¥2,769,173, and ¥771,857 annually thereafter. For secondary MI patients, the first-year cost was ¥2,781,067, and ¥1,024,076 annually thereafter. Among 28,460 UA patients, 22,358 had a primary event. The first-year cost for primary UA patients was ¥2,190,184, and ¥743,372 annually thereafter; for secondary UA patients, the first-year cost was ¥1,916,954, and ¥858,116 annually. Among 79,476 IS patients, 70,563 experienced a primary event. The first-year treatment cost was ¥2,124,713 for primary IS patients and ¥768,141 annually thereafter; for secondary IS patients, the first-year cost was ¥2,105,041 and ¥865,710 annually thereafter.
CONCLUSIONS: Based on this large and contemporary real-world study, CVD present a substantial cost burden to the Japanese healthcare system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE502
Topic
Economic Evaluation, Epidemiology & Public Health, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)